Immunotherapy using the immune checkpoint inhibitors (ICIs) anti-PD-1 (Programmed Death 1), anti-PD-L1 (Programmed Death Ligand 1), and anti-CTLA4 (Cytotoxic T-lymphocyte associated protein 4) is currently the standard of treatment for patients with advanced stages (IIIb and IV) of non-small cell lung cancer (NSCLC) [2]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.